Collection
Incretins in Metabolic Disease: Pathophysiology and Therapy
- Submission status
- Open
- Open for submission from
- 14 September 2023
- Submission deadline
- Ongoing
There is currently significant attention surrounding glucose-lowering drugs based on incretins, a group of hormones released from the intestine that play a vital role in regulating whole-body glucose metabolism. Exendin-4, a peptide constituent of the venom of the Gila Monster first isolated in the 1990s, is structurally similar to the incretin hormone glucagon-like peptide-1 (GLP-1) and has been found to stimulate insulin secretion, suppress glucagon release and enhance satiety. These potentially beneficial effects for whole-body glucose metabolism and the realisation that exendin-4 could be used as a basis for the development of GLP-1 receptor agonists (GLP-1RAs) fuelled interest to develop incretin-based therapies in type 2 diabetes. The following decades have heralded novel insights into the biology of incretins and generated several glucose-lowering drugs. In this special issue we summarise the state-of-the-art knowledge about incretins, from basic biology and treatment modalities to socioeconomic aspects of novel therapies.
Articles (9 in this collection)
-
-
Incretins: turning the venom into the antidote
Authors
- Anna Krook
- Hindrik Mulder
- Content type: Editorial
- Published: 18 August 2023
- Pages: 1762 - 1764
-
Incretins beyond type 2 diabetes
Authors
- Chantal Mathieu
- Iraj Ahmadzai
- Content type: Review
- Published: 08 August 2023
- Pages: 1809 - 1819
-
Incretins and cardiovascular disease: to the heart of type 2 diabetes?
Authors
- Anna Solini
- Domenico Tricò
- Stefano Del Prato
- Content type: Review
- Open Access
- Published: 05 August 2023
- Pages: 1820 - 1831
-
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Authors
- Christine R. Andreasen
- Andreas Andersen
- Tina Vilsbøll
- Content type: Invited Review
- Published: 27 July 2023
- Pages: 1846 - 1858
-
Socioeconomic aspects of incretin-based therapy
Authors
- Thomas Karagiannis
- Eleni Bekiari
- Apostolos Tsapas
- Content type: Review
- Open Access
- Published: 12 July 2023
- Pages: 1859 - 1868
-
Incretin hormones and type 2 diabetes
Authors
- Michael A. Nauck
- Timo D. Müller
- Content type: Review
- Open Access
- Published: 11 July 2023
- Pages: 1780 - 1795
-
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Authors
- Matthias Tschöp
- Ruben Nogueiras
- Bo Ahrén
- Content type: Review
- Open Access
- Published: 20 May 2023
- Pages: 1796 - 1808
-
The expanding incretin universe: from basic biology to clinical translation
Authors
- Daniel J. Drucker
- Jens J. Holst
- Content type: Review
- Published: 28 March 2023
- Pages: 1765 - 1779